Auro Viswabandya

Nov 7, 2024 | nature.com | Auro Viswabandya

Myelofibrosis (MF), either primary (PMF) or following essential thrombocythemia (ET) or polycythemia vera (PV), is associated with morbidity and mortality from dysregulated cytokines, cytopenias, symptomatic splenomegaly, and progression to blast-phase (BP). The only curative therapy for MF is allogeneic haematopoietic stem cell transplant (HCT) which is recommended for patients with higher-risk disease with good performance status and an available donor.

Nov 4, 2024 | onlinelibrary.wiley.com | Nihar R. Desai |Auro Viswabandya |Temerty Faculty |Jeffrey Lipton

Conflicts of Interest The authors declare no conflicts of interest. References 1, , , , and , “Post–Hematopoietic Stem Cell Transplantation Immune-Mediated Anemia: A Literature Review and Novel Therapeutics,” Blood Advances 6, no. 8 (2022): 2707–2721. 2, , , and , “Daratumumab for Delayed Red-Cell Engraftment After Allogeneic Transplantation,” New England Journal of Medicine 379, no. 19 (2018): 1846–1850.